Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LANOXIN PEDIATRIC vs LANOXIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibition of Na+/K+ ATPase leading to increased intracellular calcium and positive inotropy.
Inhibits Na+/K+ ATPase, increasing intracellular Ca2+ via Na+/Ca2+ exchange, enhancing cardiac contractility and reducing conduction through AV node.
Heart failure,Atrial fibrillation,Atrial flutter
Heart failure (NYHA class II-IV) with reduced ejection fraction,Atrial fibrillation and atrial flutter for rate control (off-label: paroxysmal supraventricular tachycardia)
Adult: Oral loading dose 0.75-1.5 mg in divided doses over 24-48 hours. Maintenance: 0.125-0.5 mg once daily. Intravenous: Loading dose 0.5-1 mg over 10-20 minutes, then maintenance 0.125-0.5 mg once daily.
0.125-0.25 mg orally once daily; loading dose 0.5-0.75 mg orally divided over 24-48 hours if rapid digitalization required.
Terminal elimination half-life is 36-48 hours in adults with normal renal function; prolonged to 3.5-5 days in anephric patients due to reduced renal clearance.
Terminal elimination half-life is approximately 36-48 hours in patients with normal renal function; prolonged to 3.5-5 days in anuria.
Hepatic via glucuronidation; substrate of P-glycoprotein; renal excretion of unchanged drug.
Primarily hepatic via CYP3A4 and renal excretion of unchanged drug; undergoes biliary excretion and enterohepatic recirculation.
Renal excretion of unchanged drug accounts for 60-80% of elimination; nonrenal clearance is 20-40% (biliary/fecal).
Renal excretion of unchanged drug (60-80%) and biliary/fecal elimination (20-40%).
20-30% bound to plasma proteins, primarily albumin.
25-30% bound primarily to albumin.
Vd is 5-10 L/kg in adults, indicating extensive tissue binding; higher in infants (up to 16 L/kg) with reduced protein binding.
Vd approximately 6-7 L/kg; indicates extensive tissue binding, particularly to cardiac muscle.
Oral: 60-80% (Lanoxin Pediatric elixir 70-85%); variable due to first-pass metabolism and P-glycoprotein effects.
Oral: 60-80%; Intravenous: 100%.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25-50%; GFR <10 m L/min: reduce dose by 50-75% or consider alternative.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 50% or use 0.125 mg every 48 hours; GFR <10 m L/min: reduce dose by 75% or use 0.0625 mg daily; monitor digoxin levels.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: avoid use or reduce dose by 50-75% with monitoring.
No specific Child-Pugh based dose adjustment; use caution in severe hepatic impairment due to potential toxicity; monitor levels.
Oral loading: 10-20 mcg/kg in divided doses over 24 hours; maintenance: 5-10 mcg/kg once daily. IV loading: 10-15 mcg/kg; maintenance: 4-8 mcg/kg once daily. Monitor levels.
Loading dose: 10-15 mcg/kg orally divided every 8 hours over 24 hours; maintenance: 5-10 mcg/kg/day orally in 2 divided doses; maximum 0.25 mg/day.
Reduced dose: initial maintenance 0.0625-0.125 mg once daily due to age-related renal impairment and increased sensitivity. Monitor renal function and serum digoxin levels.
Start with 0.0625-0.125 mg orally daily; adjust based on renal function and drug levels; due to decreased lean body mass and renal clearance.
Digitalis toxicity can cause severe arrhythmias; monitoring of serum digoxin levels required.
None; however, toxicity is common and potentially fatal. Not a formal black box warning due to age of drug.
Risk of toxicity in renal impairment, electrolyte disturbances, and drug interactions; monitor digoxin levels and ECG.
Toxicity risk: hypokalemia, hypomagnesemia, hypercalcemia increase sensitivity,Renal impairment requires dose adjustment,Digoxin immune Fab for life-threatening overdose,Pregnancy category C,Monitor serum levels and ECG
Hypersensitivity to digoxin, ventricular fibrillation, digitalis toxicity.
Hypersensitivity,Ventricular fibrillation,AV block (unless pacemaker present),Wolff-Parkinson-White syndrome with atrial fibrillation,Hypertrophic obstructive cardiomyopathy,Hypokalemia or hypercalcemia (relative)
Avoid concurrent ingestion of high-fiber foods, as they may reduce absorption. Separate dosing by at least 2 hours from meals rich in bran, oats, or other fiber. Maintain consistent dietary potassium intake; both low and high potassium can affect digoxin toxicity. Grapefruit juice may increase absorption; avoid excessive consumption.
High-fiber foods (bran) may decrease absorption; take digoxin 2 hours before or after high-fiber meals. Potassium-rich foods (bananas, oranges, spinach) can affect toxicity risk; maintain consistent intake. Avoid excessive licorice (glycyrrhizin can cause hypokalemia). Grapefruit juice may increase digoxin absorption; avoid large amounts.
First trimester: No evidence of increased risk of major malformations. Second/third trimester: Potential for fetal bradycardia, cardiac arrhythmias, and intrauterine growth restriction due to transplacental transfer and maternal hemodynamic changes.
Digoxin crosses the placenta. First trimester: No increased risk of major malformations reported in human studies; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: Risk of fetal toxicity (bradycardia, arrhythmias) if maternal serum levels are supratherapeutic; therapeutic maternal levels are generally safe. Chronic use may be associated with reduced birth weight.
Digoxin is excreted into breast milk with an M/P ratio of approximately 0.6–0.9. Levels are low (typically <1 ng/m L) and considered compatible with breastfeeding; however, monitor infant for signs of toxicity including bradycardia and feeding difficulties.
Digoxin is excreted into breast milk in low concentrations. M/P ratio approximately 0.6–0.9. At typical maternal doses (0.125–0.5 mg/day), the estimated infant dose is less than 10% of the weight-adjusted neonatal maintenance dose, usually considered compatible with breastfeeding. Monitor infant for signs of digoxin toxicity (bradycardia, poor feeding, vomiting).
Due to increased volume of distribution and renal clearance in pregnancy, higher doses (up to 30–50% increase) may be required to maintain therapeutic serum levels. Monitor serum digoxin concentrations and titrate to therapeutic range (0.5–0.9 ng/m L in heart failure; 0.8–2.0 ng/m L for arrhythmias).
Pregnancy increases glomerular filtration rate (GFR) and volume of distribution, which may lower serum digoxin concentrations; dose adjustments are often needed. Monitor serum levels and adjust dose to maintain therapeutic range (0.5–2.0 ng/m L). Consider increasing dose by 30-50% in later pregnancy if levels are low; postpartum dose may need reduction to prepregnancy levels.
Lanoxin Pediatric (digoxin) requires monitoring of renal function and serum electrolytes (especially potassium and magnesium) due to narrow therapeutic index. Check digoxin levels 6-8 hours after dose; therapeutic range 0.8-2.0 ng/m L. Avoid concurrent use with drugs that affect renal function or electrolyte balance.
Check serum digoxin level 6-8 hours after last dose; therapeutic range 0.5-2.0 ng/m L. Hypokalemia, hypomagnesemia, hypercalcemia increase toxicity risk. Use with caution in renal impairment (reduce dose). Monitor for bradycardia and arrhythmias. Avoid in patients with AV block (except pacemaker) or hypertrophic cardiomyopathy. Loading dose: 10-15 mcg/kg lean body weight. Maintenance: 0.125-0.25 mg daily. Consider drug interactions with amiodarone, verapamil, quinidine, and macrolides.
Take exactly as prescribed at the same time each day. Do not double the dose if you miss one.,Do not stop taking without consulting your doctor. Sudden withdrawal may worsen heart condition.,Watch for signs of toxicity: nausea, vomiting, diarrhea, vision changes (blurring, yellow-green halos), confusion, irregular heartbeat.,Keep all appointments for blood tests to monitor levels and kidney function.,Contact your doctor before taking any new medications, including over-the-counter drugs and supplements.,Limit alcohol and avoid potassium-sparing diuretics unless prescribed. Maintain consistent dietary intake of potassium-rich foods.
Take digoxin exactly as prescribed, usually once daily. Do not miss doses or double up.,Monitor pulse before each dose; hold and contact prescriber if heart rate <60 bpm.,Report symptoms of toxicity: nausea, vomiting, diarrhea, blurred vision, yellow-green halos, confusion, or irregular heartbeat.,Avoid over-the-counter antacids, laxatives, or kaolin-pectin; they reduce absorption. Take digoxin 2 hours apart from such products.,Maintain consistent intake of potassium-rich foods (bananas, oranges) unless otherwise instructed. Avoid excessive salt substitutes.,Keep all appointments for blood tests (digoxin levels, potassium, kidney function).,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LANOXIN PEDIATRIC vs LANOXIN, answered by our medical review team.
LANOXIN PEDIATRIC is a Cardiac Glycoside that works by Inhibition of Na+/K+ ATPase leading to increased intracellular calcium and positive inotropy.. LANOXIN is a Cardiac Glycoside that works by Inhibits Na+/K+ ATPase, increasing intracellular Ca2+ via Na+/Ca2+ exchange, enhancing cardiac contractility and reducing conduction through AV node.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LANOXIN PEDIATRIC and LANOXIN depend on the specific clinical indication. These are both Cardiac Glycoside agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LANOXIN PEDIATRIC is: Adult: Oral loading dose 0.75-1.5 mg in divided doses over 24-48 hours. Maintenance: 0.125-0.5 mg once daily. Intravenous: Loading dose 0.5-1 mg over 10-20 minutes, then maintenance 0.125-0.5 mg once daily.. The standard adult dose of LANOXIN is: 0.125-0.25 mg orally once daily; loading dose 0.5-0.75 mg orally divided over 24-48 hours if rapid digitalization required.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LANOXIN PEDIATRIC and LANOXIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LANOXIN PEDIATRIC is classified as Category C. First trimester: No evidence of increased risk of major malformations. Second/third trimester: Potential for fetal bradycardia, cardiac arrhythmias, and intrauterine growth restric. LANOXIN is classified as Category C. Digoxin crosses the placenta. First trimester: No increased risk of major malformations reported in human studies; animal studies show no teratogenicity at clinically relevant dose. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.